Streptococcus salivarius DSM 23307 Adhesion to Respiratory Epithelium
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current strains of Streptococcus salivarius have limited ability to colonize the upper respiratory tract, making them less effective in treating infections and inflammations of the respiratory system, and are potentially pathogenic.
Innovation Solution
A new strain of Streptococcus salivarius, DSM 23307, isolated from the nasopharynx, characterized by high adhesion capacity to HEp-2 cells, production of bacteriocins inhibiting S. pneumoniae and S. pyogenes, absence of virulence genes, and complete antibiotic sensitivity, is developed for enhanced colonization and treatment efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current strains of Streptococcus salivarius are used for treatment, then they can inhibit pathogenic microorganisms, but their ability to colonize the upper respiratory tract is limited
Solution Approach 1:
The patent isolates and selects a specific strain of S. salivarius (DSM 23307) with optimized parameters including high adhesion capacity to HEp-2 cells (57%), stable bacteriocin production across various culture conditions, and absence of virulence genes. This strain selection resolves the contradiction by finding a specific parameter configuration that achieves both strong pathogen inhibition and effective respiratory tract colonization
2Reliability
If Streptococcus mitis, Streptococcus sanguinis, or Streptococcus oralis are administered to interfere with pathogenic microorganisms, then they show inhibitory effects, but they are classified as potentially pathogenic species
Solution Approach 1:
The patent extracts and eliminates the harmful pathogenicity factor from the Streptococcus species by selecting S. salivarius strain DSM 23307, which has been verified to lack virulence genes through genomic analysis. This strain maintains the beneficial inhibitory activity against pathogenic microorganisms through bacteriocin production while removing the harmful pathogenic potential, thus resolving the contradiction between efficacy and safety
3Productivity
If S. salivarius K12 is administered orally, then it shows some colonizing ability, but only a small percentage of patients experience symptom improvement
Solution Approach 1:
The patent identifies and selects a superior strain (DSM 23307) with enhanced parameters compared to S. salivarius K12, specifically demonstrating 57% adhesion capacity to HEp-2 cells and stable bacteriocin production under various culture conditions (BAC and TSYE media). These optimized parameters translate to both improved colonization efficiency and enhanced therapeutic efficacy, resolving the contradiction between colonization ability and treatment effectiveness
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The new strain effectively colonizes the upper respiratory tract, inhibiting pathogenic bacteria and fungi, improving treatment outcomes for conditions like acute otitis media, nasal polyposis, and sinusitis, with improved bioavailability and stability through suitable pharmaceutical compositions.
Implementation Method 1
high adhesion capacity to the cells HEp-2 (epithelial cells of human carcinoma of the larynx) up to 57%
Implementation Method 2
production of bacteriocins inhibiting S. pneumoniae and S. pyogenes
Data Source
AI summary
The present, invention provides a new microbial strain of the species Streptococcus salivarius for use in the treatment of inflammatory processes with or without infectious etiology. A further object of the present invention compositions comprising said strain and uses thereof.